Gabe Simon

Gabe joined Vividion in 2017 to lead the proteomics platform group. His role involves a dual focus on building and scaling a cutting-edge chemical proteomics screening group, as well as the creation and oversight of a unique and enabling proteo-informatic database called the data portal. The proteomics platform group supports nearly all stages of Vividion’s drug discovery efforts and works closely with the Early Discovery group to identify and prioritize opportunities for development.

Gabe has spent the majority of his scientific career developing proteomics methodologies and novel informatic tools to derive maximum insight from them. Prior to joining Vividion, Gabe was an early employee at Abide Therapeutics where he developed gel- and mass-spectrometry-based screening workflows for the discovery and characterization of covalent serine hydrolase inhibitors that are currently undergoing clinical exploration. Gabe was a graduate student with Vividion co-founder Ben Cravatt at The Scripps Research Institute and performed post-doctoral research with Jeff Gordon at Washington University in St. Louis. He is an author or co-author of more than 30 scientific publications and three issued patents.